Role of Prohepcidin in Uremic Patients

Completed

• Conditions: Inflammation; Chronic Kidney Disease

• Registration Number: NCT01735773
• Lead Sponsor: Haseki Training and Research Hospital

Brief Summary

The investigators aimed to study the effect of prohepcidin levels on hematologic parameters and inflammatory markers in non-diabetic uremic patients. The investigators selected three groups of patients: Hemodialysis group, peritoneal dialysis group and the group with stage 4 chronic kidney disease. A control group was formed from healthy volunteers also. Each group has been planned to be formed of about 25 patients. Diabetic patients were excluded. Prohepcidin, hsCRP, IL-6, fibrinogen have been planned to be studied besides other routine biochemical analysis including hematological ones.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-01
• Primary Completion: 2011-03
• Study Completion: 2011-03
• Status Verified: 2012-11
• Study First Submitted: 2012-11-26
• Study First Submitted QC: 2012-11-27
• Last Update Submitted: 2012-11-27
• Study First Posted: 2012-11-28
• Last Update Posted: 2012-11-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• hemodialysis and peritoneal dialysis patients who had been on dialysis therapy for more than 3 months,
• age between 18-80 years,
• patients with creatinine clearance between 15-30 ml/min.

Exclusion Criteria

• age less than 18 or more than 80,
• diabetic patients,
• current active infectious or inflammatory disease.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
prohepcidin level	Six months	Prohepcidin levels will be compared with other inflammatory markers.

Secondary Outcome Measures

Name	Time	Method
Anemia and inflammatory markers	Six months	Correlations of prohepcidin levels with anemia and inflamatory markers

Trial Locations

Locations (1)

Haseki Training and Research Hospital; 🇹🇷 Istanbul, Turkey